Comparing Esmolol IV Infusion and 4% Lignocaine Nebulization for Minimizing Haemodynamic Changes during Laryngoscopy and Endotracheal Intubation: A Preoperative vs. Elective Surgery Study
- Conditions
- Health Condition 1: 8- Other Procedures
- Registration Number
- CTRI/2024/07/070665
- Lead Sponsor
- Datta Meghe Institute of Higher Education and Research
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Participants meeting specific criteria were included in the study. These criteria encompassed individuals aged between 15 to 60 years, falling within American Society of Anesthesiologists (ASA) physical status classification I and II, scheduled for elective Ear, Nose, and Throat (ENT) surgical procedures. Additionally, inclusion required participants to have provided valid informed consent, ensuring their understanding and willingness to participate in the study. These criteria aimed to establish a homogeneous participant group suitable for the investigation into the comparative efficacy of intravenous Esmolol and 4% Lignocaine nebulization in attenuating haemodynamic responses during laryngoscopy and endotracheal intubation.
Participants were excluded from the study if they did not meet the predefined inclusion criteria, including age, ASA status, and surgical type. Additionally, individuals with anticipated difficult intubation, uncontrolled hypertension or diabetes, a history of cardiac illness, neuromuscular disorders, hepatic disease, renal disease, known sensitivity to the drugs under investigation, cerebrovascular disease, or undergoing emergency surgery were excluded. Furthermore, patients with bronchial asthma or those currently receiving alpha and beta blockers were also excluded from participation. These exclusion criteria were established to mitigate confounding factors and ensure the safety and integrity of the study outcomes.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method